As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Zhejiang Dian Diagnosis is a diagnostic services provider. The company maintains more than 200 logistics centers and tested 40,000 samples daily in 2016. With ten recent mergers in China, the company is expanding into poorer provinces.
Chen Haibin
Hangzhou, Zhejiang
(571) 8893.3708
zqb@dagene.net
Hong Kong
In 2015, the company participated in a $15 million Series B funding for Ativa, a diagnostic and testing firm based in Minneapolis.
In 2015, the company invested around $4.7 million for a 20% stake in Biocore Co., Ltd., a genetic diagnosis firm based in South Korea.